美國食品藥物管理局核准新的腎癌藥物組合

FDA approves new kidney cancer drug combination

Updated at: September 28, 2026 at 12:15 AM

2026年9月24日,美國食品藥物管理局(FDA)在核准了一項用於晚期腎癌患者的新型藥物組合後,達成了一項醫學里程碑。該療法涉及將 belzutifan (WELIREG) 與 lenvatinib (LENVIMA) 結合,適用於先前已接受過免疫檢查點抑制劑治療的晚期腎細胞癌(Renal Cell Carcinoma,簡稱RCC)成年患者。此新方案尤具意義,因其將首個同類(First-in-class)的 HIF-2α 抑制劑引入了二線治療。該核准是基於第三期 LITESPARK-011 臨床試驗的結果,該試驗將此藥物組合與標準療法進行了比較。使用該組合的受試者中位無惡化存活期(Progression-free survival)為14.6個月,而對照組則為10.6個月。此外,客觀緩解率(Objective response rate)達到53%,為疾病已惡化的患者提供了具希望的替代療法。儘管該組合帶來了新希望,患者與醫療人員仍須謹慎管理潛在副作用,包括高血壓(Hypertension)、貧血(Anemia)與心臟功能障礙(Cardiac dysfunction)。藉由提供一種非免疫治療的策略,此項核准解決了關鍵的醫療需求,為正克服晚期腎癌挑戰的患者提供了至關重要的全新選擇。

On September 24, 2026, the U.S. Food and Drug Administration (FDA) reached a medical milestone by approving a new drug combination for patients with advanced kidney cancer. The treatment involves pairing belzutifan (WELIREG) with lenvatinib (LENVIMA) for adults with advanced renal cell carcinoma who have already undergone treatment with immune checkpoint inhibitors. This new protocol is particularly significant because it introduces a first-in-class HIF-2α inhibitor into the second-line setting. The approval follows the results of the phase 3 LITESPARK-011 clinical trial, which compared this combination against standard treatments. Participants using the duo demonstrated a median progression-free survival of 14.6 months, compared to 10.6 months for those in the control group. Furthermore, the objective response rate reached 53%, providing a promising alternative for those whose disease has progressed. While the combination offers new hope, patients and providers must carefully manage potential side effects, including hypertension, anemia, and cardiac dysfunction. By offering a non-immunotherapy strategy, this approval addresses a critical medical need, providing a vital new option for patients navigating the challenges of advanced kidney cancer.

noun美國食品藥物管理局
verb核准
noun腎癌
noun患者
noun藥物
verb治療
noun患者
verb治療
verb核准
noun臨床試驗
noun藥物
noun患者
noun患者
noun副作用
noun高血壓
verb治療
verb核准
adjective關鍵
noun腎癌
noun患者
🎉

End of article

You read 1 focus sentences.

Challenge Mode

Comprehension Questions

FDA 在何時核准了 belzutifan 與 lenvatinib 的藥物組合?

✓

Correct Choice

2026年9月24日

哪項臨床試驗作為此藥物組合獲批的基礎?

✓

Correct Choice

LITESPARK-011

belzutifan 的主要機轉為何?

✓

Correct Choice

缺氧誘導因子-2α (HIF-2α) 抑制劑

使用該組合療法的患者,其中位無惡化存活期為何?

✓

Correct Choice

14.6 個月

下列哪項是該治療成分已知的安全性考量?

✓

Correct Choice

高血壓與肝毒性(Hepatotoxicity)

Ringoo Icon

Learn faster with Ringoo apps

Trace your learning progress and get real-time feedback with interactive exercises.